Navigation Links
Drug-eluting stents confirmed safe, effective for long-term use

Researchers at the Rabin Medical Center in Israel have determined that the use of drug-eluting stents (DES) improves the long-term clinical outcome for patients undergoing percutaneous coronary intervention (PCI), commonly known as angioplasty. Results of this study appear in the September issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

PCI is used to treat coronary artery disease and is one of the most common medical procedures. Expert reports indicate there were 1,313,000 PCI/angioplasties conducted in the U.S. in 2006. Randomized clinical trials indicate DES decreases in-stent restenosis and the frequency of repeat revascularization procedures in patients undergoing PCI, yet questions remain about the long-term safety and/or effectiveness of DES in routine clinical practice among large unselected population cohorts.

In the current study, the Israeli team examined the benefits and long-term risks of DES by evaluating the established pattern of DES versus bare-metal stent (BMS) use in routine clinical practice in Israel. Israeli guidelines established by the Israel Heart Society and the Ministry of Health require DES be used preferentially in proximal main vessels, diabetic patients, and in long lesions to reduce restenosis.

The study population comprised all consecutive cases of PCI with stent implantation over a 4-year period at the two hospitals of the Rabin Medical Center. The entire cohort consisted of 6,583 patients, 2,633 (40%) patients with a DES and 3,950 (60%) patients with BMS. The minimal follow-up time was 6 months, and the maximal follow-up time was 5.2 years, with a mean follow-up time of 3 years. Propensity score matching and stratified analysis was used to define the clinical effectiveness and safety profile of DES versus BMS among ''all comers'' patients treated at the Center, using carefully validated long-term follow-up mortality and morbidity endpoints. Propensity score matching was performed using an algorithm to match each DES patient with a BMS patient with the closest propensity score. Each pair was used once and unpaired cases were not used in further analysis. The propensity matched group consisted of 4,398 patients (2,199 matched pairs).

The usage pattern set by the Israel Ministry of Health directives was generally followed, with 40% of the procedures including a DES. Patients who received DES were slightly younger and more likely to be diabetic. Their index intervention was less likely to be emergent. The main features associated with the DES group were the use of longer or more stents per lesion, treatment of more territories, more sites per territory and of more proximal main vessels. Of the patients with DES, 66% had a DES only, whereas 34% had a combination of a DES and a BMS.

Results show that use of DES compared with BMS reduced the occurrence of myocardial infarction (MI) (5.17% vs. 5.83%) and the need for clinically driven target vessel revascularization (TVR) (9.76% vs. 12.28%). Mortality was significantly lower in the DES group, showing a persistent benefit of DES over time (23.38% for DES vs. 26.07% in BMS).

Study leader Dr. Tamir Bental concludes, "The main effect of DES is reduced restenosis, which is evident in our analysis. This outcome was sustained over time and could certainly be a major factor contributing to the survival benefit of DES. We suggest that a possible additional factor contributing to our results could be the pattern of use of the DES in our practicetreatment of more territories and more sites per territory, probably leading to a more complete revascularization. Another salient feature was the preferential treatment of more proximal main vessel. Therefore, treatment of proximal lesions could contribute to a better outcome."


Contact: Dawn Peters

Related medicine news :

1. EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery
2. Stents May Be Effective Weapon Against Stroke
3. Stents as good as surgery for clogged carotid arteries
4. Many Dont Take Blood Thinner After Getting Stents
5. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
6. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
7. Vitamin D deficiency confirmed as common across a range of rheumatic conditions
8. The protective brain hypothesis is confirmed
9. Thrush Sufferers Seek Out Safe, Natural Remedies for Thrush, Driving a 237% Increase in Sales for "The 3 Day Thrush Cure"
10. Find Safe, Affordable Prescription Alternatives at - New Site for Discount Prescription Drugs
11. buySAFE, Inc. Releases a Breakthrough White Paper that is a Must Read for Every Internet Retailer Interested in Increasing Website Conversion
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver ... 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted an article on ... from PhenoPath Laboratories in Seattle and the University of British Columbia found that certain ...
(Date:10/13/2015)... ... October 13, 2015 , ... California ... of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned ... has spanned four decades. , Dr. McLeod’s long and successful nursing practice included ...
(Date:10/13/2015)... Grants Pass, OR (PRWEB) , ... October 13, ... ... most unconscious and reflexive activities. Yet most people do not breathe correctly. According ... Chow, PhD, and Instructor Steve Lauer, learning to breathe correctly, in concert with ...
(Date:10/13/2015)... DALLAS, Texas (PRWEB) , ... October 13, 2015 ... ... comprehensive treatment possible for children with autism, PediaPlex , a Southlake, Texas, ... value of ABA Therapy and educating military families about their options ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Fla. , Oct. 13, 2015   Vigilant ... of solutions that aid in the early detection and ... has awarded Vigilant,s founder and CEO, Matthew H.J. ... Year Award, which recognizes an entrepreneur who has made ... life sciences industry in the leadership of ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... 13, 2015   Happy Vitals ®, ... home testing kit for breast milk.  The ... an unparalleled, detailed assessment of the nutrition ... carbs and key vitamins—all charted over time ... health tracking.  In addition, Happy Vitals also offers ...
Breaking Medicine Technology: